Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Alfuzosin is a selective alpha-1 adrenergic receptor antagonist widely utilized in the management of benign prostatic hyperplasia (BPH). Chemically, its molecular formula is C20H29N5O4, and it is identified by the CAS number 73803-36-4. The drug functions by relaxing smooth muscle tissue located in the prostate gland and bladder neck, thereby improving urinary flow and reducing symptoms such as hesitancy, weak stream, and nocturia. As a non-selective alpha-blocker with high affinity for alpha-1A receptors found predominantly in the lower urinary tract, Alfuzosin offers therapeutic efficacy while minimizing cardiovascular side effects often associated with less selective agents like doxazosin or terazosin.
Available primarily as extended-release oral tablets, Alfuzosin allows for once-daily dosing, which enhances patient compliance and maintains stable plasma concentrations throughout the day. This formulation helps mitigate peak-dose related hypotension. Clinical studies have consistently demonstrated that Alfuzosin significantly improves International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax) without adversely affecting blood pressure in most patients. While generally well-tolerated, common adverse events may include dizziness, headache, fatigue, and upper respiratory tract infections. Rare but serious risks involve orthostatic hypotension, particularly during the initiation of therapy, necessitating caution in elderly patients or those on concomitant antihypertensive medications.
The pharmacokinetic profile of Alfuzosin involves rapid absorption after oral administration, with significant first-pass metabolism occurring in the liver via cytochrome P450 enzymes, specifically CYP3A4. Consequently, co-administration with strong CYP3A4 inhibitors is contraindicated due to the risk of excessive drug accumulation. Alfuzosin represents a cornerstone therapy in urology, providing effective symptom relief for millions of men suffering from BPH globally. Its mechanism of action directly addresses the pathophysiological obstruction caused by enlarged prostates, making it a preferred choice over surgical interventions for moderate cases. Ongoing research continues to explore its potential applications in other conditions involving smooth muscle dysfunction, though its primary indication remains the treatment of LUTS associated with BPH.